Cara Therapeutics Inc (NASDAQ:CARA) – Equities research analysts at Piper Jaffray Companies decreased their FY2018 earnings per share (EPS) estimates for Cara Therapeutics in a note issued to investors on Tuesday, November 6th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the biopharmaceutical company will post earnings of ($2.02) per share for the year, down from their previous forecast of ($1.83). Piper Jaffray Companies also issued estimates for Cara Therapeutics’ Q4 2018 earnings at ($0.49) EPS, Q1 2019 earnings at ($0.53) EPS, Q2 2019 earnings at ($0.51) EPS, Q3 2019 earnings at ($0.44) EPS, Q4 2019 earnings at ($0.41) EPS, FY2019 earnings at ($1.90) EPS, FY2020 earnings at ($1.90) EPS and FY2021 earnings at ($1.90) EPS.

A number of other brokerages have also issued reports on CARA. Cantor Fitzgerald set a $27.00 target price on shares of Cara Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. Zacks Investment Research upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 30th. Stifel Nicolaus raised their target price on shares of Cara Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. BidaskClub upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 10th. Finally, Canaccord Genuity raised their target price on shares of Cara Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Cara Therapeutics presently has a consensus rating of “Buy” and an average target price of $26.11.

Shares of NASDAQ CARA opened at $19.67 on Friday. Cara Therapeutics has a 1 year low of $11.46 and a 1 year high of $24.30. The company has a market cap of $774.41 million, a P/E ratio of -10.58 and a beta of 2.92.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.05). The company had revenue of $5.06 million for the quarter, compared to analysts’ expectations of $4.72 million.

In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $19.81, for a total transaction of $59,430.00. Following the transaction, the senior vice president now owns 98,000 shares of the company’s stock, valued at $1,941,380. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Derek T. Chalmers sold 20,000 shares of the stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $18.78, for a total transaction of $375,600.00. Following the transaction, the chief executive officer now directly owns 991,392 shares in the company, valued at approximately $18,618,341.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 99,484 shares of company stock worth $2,044,195. 6.70% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. raised its stake in Cara Therapeutics by 23.1% during the third quarter. BlackRock Inc. now owns 2,758,118 shares of the biopharmaceutical company’s stock worth $66,055,000 after purchasing an additional 516,870 shares during the period. Chescapmanager LLC raised its stake in Cara Therapeutics by 10.6% during the second quarter. Chescapmanager LLC now owns 1,164,431 shares of the biopharmaceutical company’s stock worth $22,299,000 after purchasing an additional 111,498 shares during the period. First Manhattan Co. raised its stake in Cara Therapeutics by 205.9% during the second quarter. First Manhattan Co. now owns 557,000 shares of the biopharmaceutical company’s stock worth $10,666,000 after purchasing an additional 374,900 shares during the period. Nexthera Capital LP raised its stake in Cara Therapeutics by 24.1% during the second quarter. Nexthera Capital LP now owns 435,800 shares of the biopharmaceutical company’s stock worth $8,346,000 after purchasing an additional 84,750 shares during the period. Finally, Marshall Wace LLP purchased a new position in Cara Therapeutics during the second quarter worth approximately $6,682,000. 48.88% of the stock is currently owned by institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: What does RSI mean?

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.